Safety and efficacy of moxonidine in mild to moderate hypertension.

Abstract

AIMS:

Moxonidine, a new imidazoline II receptor agonist was evaluated in patients with essential hypertension.

METHODOLOGY:

After an informed consent, 16 patients with essential hypertension were recruited. After a wash out period, the patients received increasing doses of Moxonidine (maximum dose 0.6 mg) for four weeks to control the blood pressure.

RESULTS:

The mean reduction in blood pressure (systolic/diastolic) was 17.6/14.5 mm Hg in supine position and 18.2/12.6 mm Hg in standing position. The significant side effect was observed only in one patient.

CONCLUSIONS:

Moxonidine thus appears to be safe and effective antihypertensive drug in patients with essential hypertension.

• Authors: S Jain, P Malhotra, S Kumari, S Varma
• Journal: The Journal of the Association of Physicians of India (J Assoc Physicians India) Vol. 49 Pg. 829-30 (Aug 2001) ISSN: 0004-5772 [Print] India
• PMID: 11837474 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antihypertensive Agents
• Imidazoles
• moxonidine

Topics

• Adult
• Aged
• Antihypertensive Agents (adverse effects, therapeutic use)
• Blood Pressure (drug effects, physiology)
• Epistaxis (chemically induced)
• Female
• Humans
• Hypertension (drug therapy, physiopathology)
• Imidazoles (adverse effects, therapeutic use)
• Male
• Middle Aged
• Severity of Illness Index